CSIMarket Company Name, Ticker, Industry, else..
 
Acer Therapeutics Inc   (ACER)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 24
 Employees 40
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -48
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 0

Acer Therapeutics Inc
Acer Therapeutics Inc. is a pharmaceutical company that focuses on the development and commercialization of therapies for serious rare and ultra-rare diseases. The company's mission is to provide innovative treatments for patients suffering from diseases with limited or no available therapeutic options. Acer Therapeutics aims to address unmet medical needs and improve the quality of life for patients through its drug development programs. The company's pipeline primarily includes treatments for genetic disorders where there are currently no approved therapies.


   Company Address: One Gateway Center Newton 2458 MA
   Company Phone Number: 902-6100   Stock Exchange / Ticker: ACER


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMRN   -0.17%    
LLY   -2.41%    
TEVA   -3.39%    
UTHR   -0.89%    
VRTX   -1.94%    
VTRS   -5.08%    
• View Complete Report
   



Acer Therapeutics Inc

Acer Therapeutics Inc Reports Revenue of $0.37179 Million in Q3 2023 Financial Report amidst Concerns of Declining Stock Performance



The stock performance of a company plays a vital role in determining its overall financial health. Acer Therapeutics Inc, a major player in the pharmaceutical preparations industry, has experienced a decline in its stock price over the past week, negatively impacting its year-to-date performance. This article aims to provide an overview of the recent trends seen in Acer Therapeutics Inc's stock performance, along with insights into the company's financial records and future expectations.
Stock Performance
Over the past week, Acer Therapeutics Inc's stock has experienced a decline, although the exact percentage decrease is undisclosed in the provided information. This downtrend has brought the company's year-to-date performance to a staggering -74.81%. Consequently, investors may have concerns about the company's financial stability, prompting a closer examination of its financial records.
Acer Therapeutics Inc

Acer Therapeutics Inc Shows Promising Turnaround, Slashes Operating Loss to $-4.294477 Million in Recent Fiscal Period

Acer Therapeutics Inc, a major pharmaceutical preparations company, recently released its financial report for the April to June 2023 reporting cycle. Surprising investors, there were no moderations at the top-line during this period. However, the company did experience an operating loss of $-4.294477 million, which is a significant improvement from the operating loss of $-7.064846 million reported in the second quarter of 2022.
These reports shed light on the current state of Acer Therapeutics Inc, indicating that the company is making strides to refine its business strategy. As a rising business, it is crucial for Acer to compete effectively in order to achieve further growth and success. Yet, these figures also reveal the challenges faced by the company, as it recorded a net deficit of $-8.091 million in the second quarter of 2023, compared to a net deficit of $-2.667 million in the same period last year.
Acer Therapeutics Inc

Acer Therapeutics Inc. Reports Promising Fiscal Results for Q1 2023 in Major Pharmaceuticals Market

The pharmaceutical industry has always been one of the most lucrative businesses in the world. However, it is not without its share of challenges, as evidenced by the recent earnings of Acer Therapeutics Inc. reported for the first quarter of 2023.
The company's operating loss of $-4.989301 million, without any mention of revenue, comes as a surprise to many industry insiders. However, this loss is significantly lower when compared to the first quarter of 2022, which saw the company report an operating loss of $-7.04724 million.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com